6-Mercaptopurine | CAS#50-44-2 | MedKoo Biosciecnes

MedKoo Cat#: 100590 | Name: 6-Mercaptopurine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mercaptopurine is a thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.

Chemical Structure

6-Mercaptopurine

CAS#50-44-2

Theoretical Analysis

MedKoo Cat#: 100590

Name: 6-Mercaptopurine

CAS#: 50-44-2

Chemical Formula: C5H4N4S

Exact Mass: 152.0157

Molecular Weight: 152.18

Elemental Analysis: C, 39.46; H, 2.65; N, 36.82; S, 21.07

Price and Availability

Size	Price	Availability	Quantity
5g	USD 250.00	2 weeks
25g	USD 550.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

6112-76-1 (hydrate) 50-44-2

Synonym

6-Thiohypoxanthine; 6-thiopurine; 6-mercaptopurine;

IUPAC/Chemical Name

1H-purine-6(7H)-thione

InChi Key

GLVAUDGFNGKCSF-UHFFFAOYSA-N

InChi Code

InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)

SMILES Code

S=C1NC=NC2=C1NC=N2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Mercaptopurine is used to treat leukemia. It is also used for pediatric non-Hodgkin's lymphoma, polycythemia vera,[citation needed] psoriatic arthritis,[citation needed] and inflammatory bowel disease (such as Crohn's disease and ulcerative colitis). It has demonstrated some in vitro effectiveness against Mycobacterium paratuberculosis. DRUG DESCRIPTION PURINETHOL (mercaptopurine) was synthesized and developed by Hitchings, Elion, and associates at the Wellcome Research Laboratories. Mercaptopurine, known chemically as 1,7-dihydro-6H-purine-6-thione monohydrate, is an analogue of the purine bases adenine and hypoxanthine. PURINETHOL is available in tablet form for oral administration. Each scored tablet contains 50 mg mercaptopurine and the inactive ingredients corn and potato starch, lactose, magnesium stearate, and stearic acid. Mechanism of action Mercaptopurine (6-MP) competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). This intracellular nucleotide inhibits several reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP). In addition, 6-methylthioinosinate (MTIMP) is formed by the methylation of TIMP. Both TIMP and MTIMP have been reported to inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. Experiments indicate that radiolabeled mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine. Some mercaptopurine is converted to nucleotide derivatives of 6-thioguanine (6-TG) by the sequential actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase, converting TIMP to thioguanylic acid (TGMP). Animal tumors that are resistant to mercaptopurine often have lost the ability to convert mercaptopurine to TIMP. However, it is clear that resistance to mercaptopurine may be acquired by other means as well, particularly in human leukemias. It is not known exactly which of any one or more of the biochemical effects of mercaptopurine and its metabolites are directly or predominantly responsible for cell death.

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 152.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hareedy MS, El Desoky ES, Woillard JB, Thabet RH, Ali AM, Marquet P, Picard N. Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015 Aug 3:1-15. [Epub ahead of print] PubMed PMID: 26237184.